Skip to main content
Premium Trial:

Request an Annual Quote

Cellectis, Genoway Reach Agreement on Terminated License

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Cellectis and Genoway said that they have reached an agreement on how to handle orders of products covered by a licensing agreement between the firms that was terminated in late 2008.

In December 2008, Cellectis terminated a non-exclusive license that granted Genoway access to patents covering certain uses of homologous recombination. The initial license had been signed in 2001.

The firms said yesterday that under their agreement Genoway would be allowed to deliver the orders placed after termination of the deal and before Nov. 12, 2009. Paris-based Cellectis said in a statement that a visa of Cellectis will be attached to the delivery of such orders.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.